The Impact of Camostat Mesilate on COVID-19 Infection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

April 4, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

May 1, 2023

Conditions
Corona Virus Infection
Interventions
DRUG

Camostat Mesilate

Serine protease inhibitor that blocks TMPRSS-2 mediated cell entry of SARS-CoV-2

DRUG

Placebo oral tablet

Placebo

Trial Locations (11)

2400

Bispebjerg hospital, Copenhagen

3400

Northzealands hospital - Hillerød, Hillerød

5000

Dept. of Infectious Diseases, Odense University Hospital, Odense

7400

Herning Regional Hospital, Herning

8200

Department for Infectious Diseases, Aarhus University Hospital, Aarhus N

8600

Silkeborg Hospital, Silkeborg

8700

Horsens Regional Hospital, Horsens

8900

Randers Regional Hospital, Randers

Unknown

Region Hospital North Jutland, Hjørring

Department of Infectious Diseases, Aalborg

Örebro Hsopital, Örebro

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT04321096 - The Impact of Camostat Mesilate on COVID-19 Infection | Biotech Hunter | Biotech Hunter